SynthesisJAMA network open2023
Use of Antihypertensives, Blood Pressure, and Estimated Risk of Dementia in Late Life: An Individual Participant Data Meta-Analysis.
Synthesis in JAMA network open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 6 syntheses or guidelines pooled it, 84 citations in OpenAlex.
- Clinical outcomes of antihypertensive medication use in people with dementia: a systematic review and meta-analysis.GeroScience · 2026Pooled it
- The Japanese Society of Hypertension Guidelines for the management of elevated blood pressure and hypertension 2025 (JSH2025).Hypertension research : official journal of the Japanese Society of Hypertension · 2026Guideline
- Systemic medications and dementia risk: a systematic umbrella review.Molecular psychiatry · 2025Pooled it
- Is hypertension negatively associated with memory performance in women during climacteric? A systematic review.BMC women's health · 2025Pooled it
- The impact of hypertension prevention and modification on dementia burden: A systematic review of economic studies.The journal of prevention of Alzheimer's disease · 2025Pooled it
- Blood Pressure, Antihypertensive Use, and Late-Life Alzheimer and Non-Alzheimer Dementia Risk: An Individual Participant Data Meta-Analysis.Neurology · 2024Pooled it
- Blood pressure parameters and cognitive decline and dementia after stroke or transient ischemic attack: results from the PROGRESS trial.American journal of hypertension · 2026Trial
- Blood pressure reduction and all-cause dementia in people with uncontrolled hypertension: an open-label, blinded-endpoint, cluster-randomized trial.Nature medicine · 2025Trial
- Long-Term Effect of Intensive vs Standard Blood Pressure Control on Mild Cognitive Impairment and Probable Dementia in SPRINT.Neurology · 2025Trial
- Delirium in Patients With Traumatic Brain Injury and Long-Term Cognitive Decline: A Global Federated Real World Data Analysis.European journal of clinical investigation · 2026Article
- Rising Comorbid Alzheimer's and Hypertension Mortality in Older Adults in the United States: Trends and Disparities From a 21-Year CDC WONDER Analysis (1999-2019).Journal of clinical hypertension (Greenwich, Conn.) · 2026Article
- Natriuretic Peptides as a Biomarker of Cognitive Decline in Hypertension.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2026Review
- Associations of antihypertensive, antidiabetic, and antihyperlipidemic medications with cognitive performance in an Asian population.GeroScience · 2026Article
- Predictors of cognitive resilience in the old-old: An observational study using real-world electronic health record data.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Observational
- Harms of Continued Antihypertensives: An Overview of Reviews.Drugs & aging · 2026Review
- Twenty-four-hour blood pressure and CSF biomarkers of Alzheimer's disease and related dementias in a community cohort.GeroScience · 2026Article
- Cardiovascular-kidney-metabolic syndrome stages 0-3 and cognitive decline in Chinese adults: a longitudinal analysis from the China health and retirement longitudinal study.BMC cardiovascular disorders · 2026Article
- Article
- The Role of Posttraumatic Stress Disorder as a Risk Factor for Dementia: A Meta-Analysis.Journal of geriatric psychiatry and neurology · 2026Review
- Angiotensin II-Stimulating Antihypertensive Medications and Dementia-Related Neuropathology.JAMA network open · 2026Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
51 authors at 20 institutions in 16 countries.
Funding
Abstract
Importance: The utility of antihypertensives and ideal blood pressure (BP) for dementia prevention in late life remains unclear and highly contested. Objectives: To assess the associations of hypertension history, antihypertensive use, and baseline measured BP in late life (age >60 years) with dementia and the moderating factors of age, sex, and racial group. Data Source and Study Selection: Longitudinal, population-based studies of aging participating in the Cohort Studies of Memory in an International Consortium (COSMIC) group were included. Participants were individuals without dementia at baseline aged 60 to 110 years and were based in 15 different countries (US, Brazil, Australia, China, Korea, Singapore, Central African Republic, Republic of Congo, Nigeria, Germany, Spain, Italy, France, Sweden, and Greece). Data Extraction and Synthesis: Participants were grouped in 3 categories based on previous diagnosis of hypertension and baseline antihypertensive use: healthy controls, treated hypertension, and untreated hypertension. Baseline systolic BP (SBP) and diastolic BP (DBP) were treated as continuous variables. Reporting followed the Preferred Reporting Items for Systematic Review and Meta-Analyses of Individual Participant Data reporting guidelines. Main Outcomes and Measures: The key outcome was all-cause dementia. Mixed-effects Cox proportional hazards models were used to assess the associations between the exposures and the key outcome variable. The association between dementia and baseline BP was modeled using nonlinear natural splines. The main analysis was a partially adjusted Cox proportional hazards model controlling for age, age squared, sex, education, racial group, and a random effect for study. Sensitivity analyses included a fully adjusted analysis, a restricted analysis of those individuals with more than 5 years of follow-up data, and models examining the moderating factors of age, sex, and racial group. Results: The analysis included 17 studies with 34 519 community dwelling older adults (20 160 [58.4%] female) with a mean (SD) age of 72.5 (7.5) years and a mean (SD) follow-up of 4.3 (4.3) years. In the main, partially adjusted analysis including 14 studies, individuals with untreated hypertension had a 42% increased risk of dementia compared with healthy controls (hazard ratio [HR], 1.42; 95% CI 1.15-1.76; P = .001) and 26% increased risk compared with individuals with treated hypertension (HR, 1.26; 95% CI, 1.03-1.53; P = .02). Individuals with treated hypertension had no significant increased dementia risk compared with healthy controls (HR, 1.13; 95% CI, 0.99-1.28; P = .07). The association of antihypertensive use or hypertension status with dementia did not vary with baseline BP. There was no significant association of baseline SBP or DBP with dementia risk in any of the analyses. There were no significant interactions with age, sex, or racial group for any of the analyses. Conclusions and Relevance: This individual patient data meta-analysis of longitudinal cohort studies found that antihypertensive use was associated with decreased dementia risk compared with individuals with untreated hypertension through all ages in late life. Individuals with treated hypertension had no increased risk of dementia compared with healthy controls.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.